• Prescribing Information
  • Medical Information
  • How TRUMENBA Works​​​​​​

    TRUMENBA targets a gene found in >99% of invasive MenB disease strains2​​​​​​​

    TRUMENBA works by targeting both subfamilies, A and B, of a lipoprotein—factor H binding protein (fHBP)—for which the gene is found in more than 99% of invasive MenB strains.2​​​​​​​​​​​​
    ​​​​​​​

    The fHBP Discovery

    ​​Pfizer used a combined biochemical and immunological screening approach to identify surface-expressed proteins on MenB strains that were capable of producing antibodies that could kill diverse meningococcal strains. During this process, fHBP elicited robust bactericidal responses.1
    ​​​​​​​

    ​​​​​​​​​​​​​

    Contact your Pfizer Sales Representative or call a Vaccine Specialist at 
    ​​​​​​​1-844-439-2571.


    References:
    1. Trumenba [prescribing information]. Philadelphia, PA: Pfizer Inc; 2019.
    2. Wang X, Cohn A, Comanducci M, et al. Prevalence and genetic diversity of candidate vaccine antigens among invasive Neisseria meningitidis isolates in the United States. Vaccine. 2011;29(29-30):4739-4744.
    3. Jiang HQ, Hoiseth SK, Harris SL, et al. Broad vaccine coverage predicted for a bivalent recombinant factor H binding protein based vaccine to prevent serogroup B meningococcal disease. Vaccine. 2010;28(37):6086-6093.
    4. Tully J, Viner RM, Coen PG, et al. Risk and protective factors for meningococcal disease in adolescents: matched cohort study. BMJ. 2006;332(7539):445-450.
    5. ​​​​​​​Data on file. Pfizer Inc, New York, NY.
    6. ​​​​​​​Centers for Disease Control and Prevention. Meningococcal disease. Centers for Disease Control and Prevention website. http://www.cdc.gov/meningococcal/index.html. Updated January 21, 2020. Accessed July 6, 2020.
    7. ​​​​​​​Dwilow R, Fanella S. Invasive meningococcal disease in the 21st century—an update for the clinician. Curr Neurol Neurosci Rep. 2015;15(2):1-9.
    8. Ewald AJ, McKeag DB. Meningitis in the athlete. Curr Sports Med Rep. 2008;7(1):22-27.

    About

    • How TRUMENBA Works
    • Tru Patient Stories
    • Are Your Patients Protected?
    • CDC Recommendations

    Pfizer TruSupport

    • Ordering options
    • Patient coverage confirmation
    • Essential tools
    • Resources for your practice
    Find out about TruSupport

    Why adolescents and young adults?

    Typical adolescent and young adult behaviors increase MenB risk.4,6-8

    Learn about MenB

    Coadministration with TRUMENBA

    TRUMENBA is the only MenB vaccine that demonstrated cross-coverage of diverse MenB strains1

    See the data

    Indication

    • Trumenba is a vaccine indicated for active immunization to prevent invasive disease caused by Neisseria meningitidis serogroup B. Trumenba is approved for use in individuals 10 through 25 years of age
    • The effectiveness of the two-dose schedule of Trumenba against diverse N meningitidis serogroup B strains has not been confirmed
    • Severe allergic reaction after a previous dose of Trumenba is a contraindication
    • Some individuals with altered immunocompetence may have reduced immune responses to Trumenba
    • Persons with certain complement deficiencies and persons receiving treatment that inhibits terminal complement activation (for example, eculizumab) are at increased risk for invasive disease caused by Neisseria meningitidis serogroup B even if they develop antibodies following vaccination with Trumenba
    • As with any vaccine, vaccination with Trumenba may not protect all vaccine recipients against N meningitidis serogroup B infections
    • Syncope (fainting) can occur in association with administration of injectable vaccines, including Trumenba. Procedures should be in place to avoid injury from fainting
    • In clinical studies, the most common solicited adverse reactions in adolescents and young adults were pain at injection site (≥85%), fatigue (≥60%), headache (≥55%), and muscle pain (≥35%). Nausea was reported in up to 24% of adolescents in early phase studies
    • Sufficient data are not available on the safety and effectiveness of using Trumenba and other meningococcal group B vaccines interchangeably to complete the vaccination series
    • Safety and effectiveness have not been established in pregnant women
    • Trumenba is a vaccine indicated for active immunization to prevent invasive disease caused by Neisseria meningitidis serogroup B. Trumenba is approved for use in individuals 10 through 25 years of age
    • The effectiveness of the two-dose schedule of Trumenba against diverse N meningitidis serogroup B strains has not been confirmed

    Please see full Prescribing Information.​​​​​​​